{"id":15634,"date":"2024-09-10T04:00:40","date_gmt":"2024-09-10T04:00:40","guid":{"rendered":"http:\/\/TheNextWeb=1410089"},"modified":"2024-09-10T04:00:40","modified_gmt":"2024-09-10T04:00:40","slug":"cambridge-startup-analyses-multi-omics-data-to-discover-new-heart-drugs","status":"publish","type":"post","link":"https:\/\/www.londonchiropracter.com\/?p=15634","title":{"rendered":"Cambridge startup analyses \u2018multi-omics\u2019 data to discover new heart drugs"},"content":{"rendered":"\n
<\/div>\n

Cambridge-based CardiaTec has raised $6.5mn to accelerate drug discovery for cardiovascular diseases, such as heart attacks and strokes.<\/p>\n

Cardiovascular diseases are the leading cause of death globally, claiming the lives of 17.9 million<\/a> people each year. Yet our knowledge of their underlying biology is still limited, hindering the effectiveness of clinical trials and drug solutions.<\/p>\n

CardiaTec aims to address this knowledge gap with a drug discovery platform that leverages AI<\/a> to analyse human tissue \u201cmulti-omics\u201d data.<\/p>\n

Mutli-omics is a biological analysis approach which combines the study of multiple \u201comes,\u201d the sets of various biological molecules or entities within a cell or organism. These include the genome, the transcriptome, the proteome, and the epigenome.<\/p>\n

By analysing multi-omics data, CardiaTec\u2019s platform investigates relationships that stretch across every level of biology to shed light on how cardiovascular diseases develop.<\/p>\n

Uncovering drug targets<\/h2>\n
\n
<\/p>\n

TNW Conference 2025 – Back to NDSM on June 19-20, 2025 – Save the date!<\/p>\n

As we wrapped up our incredible 2024 edition, we’re pleased to announce our return to Amsterdam NDSM in 2025. Registration now!<\/p>\n

<\/a><\/div>\n<\/div>\n

The startup<\/a> is focusing in particular on uncovering drug targets: specific molecules within the body that are linked with a disease\u2019s progress and can be affected by a drug to achieve the intended therapeutic effect.<\/p>\n

CardiaTec\u2019s technology uses computational methods to identify and prioritise dysregulated drug targets and pathways associated with the disease.<\/p>\n

\u201cThis approach enables the discovery of novel drug targets with well-defined mechanisms of action, increasing the likelihood of successful preclinical and subsequent clinical translation,\u201d Raphael Peralta, the company\u2019s co-founder and CEO, told TNW.<\/p>\n

CardiaTec is also building the first and largest human heart tissue multi-omics dataset. To do this, it has established a network of 65 hospitals across the UK and the US.<\/p>\n

With the fresh round, the company plans to expand its platform and move proprietary drug targets towards the preclinical stage.<\/p>\n

\u201cWe have identified our first therapeutic targets,\u201d Peralta said.<\/p>\n

California-based Montage Ventures led the company\u2019s new seed round. Individual investors and VC firms also participated, including APEX Ventures and Dr Maximilien Levesque, CEO and co-founder of drug discovery startup Aqemia.<\/p>\n

Peralta founded CardiaTech in 2021, alongside Namshik Han (CTO) and Thelma Zablocki (COO). The trio spun it out from the Han Lab at the University of Cambridge.<\/p>\n

Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Cambridge-based CardiaTec has raised $6.5mn to accelerate drug discovery for cardiovascular diseases, such as heart attacks and strokes. Cardiovascular diseases are the leading cause of death globally, claiming the lives of 17.9…<\/p>\n","protected":false},"author":1,"featured_media":15635,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=\/wp\/v2\/posts\/15634"}],"collection":[{"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15634"}],"version-history":[{"count":0,"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=\/wp\/v2\/posts\/15634\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=\/wp\/v2\/media\/15635"}],"wp:attachment":[{"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.londonchiropracter.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}